DeepMed Research

OMEROS CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $238.1M

Website: http://www.omeros.com/

Clinical Trials

A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement

Phase 3

Completed

Conditions: Unilateral Cataract Extraction
Congenital Cataract

Interventions: Drug: OMS302
Drug: Phenylephrine HCl

First Posted Date: 2014-05-07

Last Posted Date: 2021-07-22

Lead Sponsor: Omeros Corporation

Target Recruit Count: 78

Registration Number: NCT02132312

Intraoperative Floppy Iris Syndrome Undergoing Intraocular Lens Replacement Surgery

Phase 3

Terminated

Conditions: Intraocular Lens Replacement
Intraoperative Floppy Iris Syndrome

Interventions: Drug: Part 1 OMS302
Drug: Part 2 OMS302
Drug: Part 2 Placebo

First Posted Date: 2014-03-21

Last Posted Date: 2018-03-13

Lead Sponsor: Omeros Corporation

Target Recruit Count: 18

Registration Number: NCT02093689

Locations: 🇩🇪
Omeros Investigational Site, Bochum, Germany

Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease

Phase 2

Terminated

Conditions: Huntington's Disease

Interventions: Drug: OMS643762
Drug: Placebo

First Posted Date: 2014-02-28

Last Posted Date: 2018-10-22

Lead Sponsor: Omeros Corporation

Target Recruit Count: 22

Registration Number: NCT02074410

Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: Placebo
Drug: OMS643762

First Posted Date: 2013-09-27

Last Posted Date: 2018-10-22

Lead Sponsor: Omeros Corporation

Target Recruit Count: 40

Registration Number: NCT01952132

Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

Phase 3

Completed

Conditions: Intraocular Lens Replacement

Interventions: Drug: Placebo
Drug: OMS302

First Posted Date: 2012-04-18

Last Posted Date: 2017-06-14

Lead Sponsor: Omeros Corporation

Target Recruit Count: 416

Registration Number: NCT01579565

Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

Phase 3

Completed

Conditions: Intraocular Lens Replacement

Interventions: Drug: OMS302
Drug: Placebo

First Posted Date: 2011-10-18

Last Posted Date: 2014-08-21

Lead Sponsor: Omeros Corporation

Target Recruit Count: 405

Registration Number: NCT01454063

Safety and Efficacy of OMS103HP-S Administered in Joint Irrigation Solution to Subjects Undergoing Arthroscopic Meniscectomy

Phase 3

Completed

Conditions: Meniscal Tear

Interventions: Drug: Vehicle
Drug: OMS103HP-S

First Posted Date: 2011-08-01

Last Posted Date: 2018-10-26

Lead Sponsor: Omeros Corporation

Target Recruit Count: 344

Registration Number: NCT01406561

Locations: 🇺🇸
Orthopedic Surgery Center, Seattle, Washington, United States

Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR)

Phase 2

Completed

Conditions: Cataract

Interventions: Drug: OMS302 Anti-inflammatory Solution
Drug: OMS302 Solution
Drug: Balanced Salt Solution (BSS) Solution
Drug: OMS302 Mydriatic Solution

First Posted Date: 2010-09-01

Last Posted Date: 2014-08-28

Lead Sponsor: Omeros Corporation

Target Recruit Count: 223

Registration Number: NCT01193127

Pharmacokinetic, Safety and Efficacy Study of OMS201 in Subjects Undergoing Retrograde Ureteroscopic Removal of Upper Urinary Tract Stones

Phase 1

Completed

Conditions: Urinary Calculi
Urinary Tract Stones
Urinary Stones
Kidney Stones
Renal Calculi

Interventions: Drug: Vehicle
Drug: OMS201

First Posted Date: 2009-03-06

Last Posted Date: 2012-10-12

Lead Sponsor: Omeros Corporation

Target Recruit Count: 18

Registration Number: NCT00857090

Locations: 🇺🇸
Urology Associates, Nasville, Tennessee, United States
🇺🇸
University of California Irvine Medical Center, Orange, California, United States
🇺🇸
Urology Center of Colorado, Denver, Colorado, United States

and more 1 locations

Exploratory Study of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction by Phacoemulsification.

Phase 1

Completed

Conditions: Cataract Extraction

Interventions: Drug: OMS302-PE
Drug: Vehicle
Drug: OMS302

First Posted Date: 2008-07-24

Last Posted Date: 2014-07-18

Lead Sponsor: Omeros Corporation

Target Recruit Count: 60

Registration Number: NCT00721695

Locations: 🇺🇸
Shasta Eye Medical Group, Redding, California, United States
🇺🇸
Davis Duehr Dean, Madison, Wisconsin, United States
🇺🇸
Silverstein Eye Centers, Kansas City, Missouri, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy